ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General `
Table 1 gN 9 " Number of patients (n = 42)
Sex, n (%) Male 25 (59.5) Female 17 (40.5) Age (years)a
6 7 [ 2 7 8 1 ] Body surface area (m2)a 1 . 6 0 [ 1 . 2 1 2 . 0 0 ] Pemetrexed dose (mg/m2)a
4 9 5 [ 4 5 7 5 1 3 ] Carboplatin dose (target AUC)a 5 [ 4 6 ] Co-administered bevacizumab, Yes 12 (28.6) n (%) No 30 (71.4) Bevacizumab dose (mg/kg)a
1 5 [ 1 3 1 5 ] Prior chemotherapy, 15 (35.7) 27 (64.3) Treatment linea 1 [ 1 2 ] Number of cyclesa 4 [ 1 8 ] Regular use of NSAIDs, 7 (16.7) 35 (83.3) Regular use of ACE/ARBs, 9 (21.4) 33 (78.6) Regular use of PPIs, Co-administered ZOL, 5 (11.9) 37 (88.1)% Co-administered radiocontrast agents, 16 (38.1) 26 (61.9) Baseline WBC (1103cells/mm3)a 5 . 8 [ 3 . 2 3 1 . 0 ] ANC (1103cells/mm3)a 3 . 9 [ 1 . 5 2 8 . 1 ] HGB (g/dL)a 1 2 . 7 [ 8 . 6 1 5 . 7 ] PLT (1104cells/mm3)a 2 4 . 8 [ 1 2 . 2 5 0 . 8 ] Baseline AST (U/L)a
2 3 [ 1 1 5 2 ] ALT (U/L)a 1 8 [ 7 4 6 ] Baseline CCr (mL/min)a 6 0 . 3 [ 2 6 . 0 9 1 . 9 ]
d MbP?_ % * + &P &F